Skip to Main Content
Table 1

Summary of Inhibition of KIM 127–stimulated THP-1 Adhesion to GP Ibα by Antibodies or Soluble Ligands

Antibody or ligandReceptor (epitope)Percent inhibition
IB4 Anti-CD18 99 ± 1 
TS1/22 Anti-CD11a (I domain) 10 ± 13 
LPM19c Anti-CD11b (I domain) 92 ± 12 
Polyclonal Anti-GP Ibα 80 ± 17 
Polyclonal Rabbit IgG control 16 ± 20 
VM16d Anti-GP Ibα (aa residues 201–268) 83 ± 16 
AP1 Anti-GP Ibα (aa residues 201–268) 86 ± 10 
AK2 Anti-GP Ibα (aa residues 36–59) 16 ± 6 
SZ2 Anti-GP Ibα (sulfated tyrosine residues 269–282) 8 ± 6 
WM23 Anti-GP Ibα (macroglycopeptide) 11 ± 5 
7E3 Anti-GP IIb-IIIa, -αvβ3, –Mac-1 16 ± 8 
10E5 Anti-GP IIb-IIIa 18 ± 6 
Fibrinogen (2 μM) Mac-1 99 ± 1 
P2γ377–395 (10 μM) Mac-1 
Heparin (200 U/ml) Mac-1 93 ± 9 
vWF A1 (20 μg/ml) GP Ibα 83 ± 13 
Antibody or ligandReceptor (epitope)Percent inhibition
IB4 Anti-CD18 99 ± 1 
TS1/22 Anti-CD11a (I domain) 10 ± 13 
LPM19c Anti-CD11b (I domain) 92 ± 12 
Polyclonal Anti-GP Ibα 80 ± 17 
Polyclonal Rabbit IgG control 16 ± 20 
VM16d Anti-GP Ibα (aa residues 201–268) 83 ± 16 
AP1 Anti-GP Ibα (aa residues 201–268) 86 ± 10 
AK2 Anti-GP Ibα (aa residues 36–59) 16 ± 6 
SZ2 Anti-GP Ibα (sulfated tyrosine residues 269–282) 8 ± 6 
WM23 Anti-GP Ibα (macroglycopeptide) 11 ± 5 
7E3 Anti-GP IIb-IIIa, -αvβ3, –Mac-1 16 ± 8 
10E5 Anti-GP IIb-IIIa 18 ± 6 
Fibrinogen (2 μM) Mac-1 99 ± 1 
P2γ377–395 (10 μM) Mac-1 
Heparin (200 U/ml) Mac-1 93 ± 9 
vWF A1 (20 μg/ml) GP Ibα 83 ± 13 

The adhesion of cytokine-treated THP-1 cells to glycocalicin (GP Ibα)–coated microtiter wells was stimulated by the addition of KIM 127 (5 μg/ml) in the presence and absence of antibodies directed to or soluble ligands of Mac-1 and GP Ibα. Polyclonal antibodies were added at 20 μg/ml and purified mAbs at 10 μg/ml as described in Materials and Methods. Soluble ligand concentrations are indicated. CD11/CD18 mAbs included IB4, TS1/22, and LPM19c; GP Ibα mAbs used were AK2, AP1, VM16d, SZ2, and WM23. Data are expressed as percent inhibition of maximal KIM-stimulated adhesion by the antibodies or soluble ligands (mean ± SD, n = 3–5). aa, amino acids.

Close Modal

or Create an Account

Close Modal
Close Modal